Lv4
728 积分 2022-07-21 加入
The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care
18天前
已完结
Costimulatory biomarker-specific CD28 PET for early prediction of the response to PD-1 blockade in lung cancer
18天前
已完结
Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
18天前
已关闭
Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRAS G12C -Mutant NSCLC for Immune Checkpoint Blockade
18天前
已完结
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
18天前
已完结
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes
18天前
已完结
The antibiotic-immunotherapy interaction in NSCLC: a systematic review and meta-analysis of 54,250 patients across three outcomes
18天前
已关闭
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression
19天前
已完结
Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
19天前
已关闭
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
19天前
已完结
皖公网安备34019202002308
